The estrogen hypothesis of Schizophrenia implicates glucose metabolism: Association study in three independent samples by Olsen, Line et al.
BioMed CentralBMC Medical Genetics
ssOpen AcceResearch article
The estrogen hypothesis of Schizophrenia implicates glucose 
metabolism: Association study in three independent samples
Line Olsen1, Thomas Hansen1,7, Klaus D Jakobsen1,7, Srdjan Djurovic2, 
Ingrid Melle2, Ingrid Agartz3, Haakan Hall3, Henrik Ullum4, Sally Timm5, 
August G Wang6, Erik G Jönsson3, Ole A Andreassen2 and Thomas Werge*1
Address: 1Research Institute of Biological Psychiatry, Sct. Hans Hospital, DK-4000 Roskilde, Denmark, 2TOP-project, Department of Psychiatry, 
Ullevål University Hospital, Institute of Psychiatry, University of Oslo, Oslo, Norway, 3Human Brain Informatics (HUBIN), Department of Clinical 
Neuroscience, Psychiatry Section, Karolinska Institutet and Hospital, Stockholm, Sweden, 4Department of Clinical Immunology, Rigshospitalet, 
Copenhagen, Denmark, 5University Department of Psychiatry, Frederiksberg, DK-2000 Frederiksberg, Denmark, 6University Department of 
Psychiatry, Amager, DK-2300 Copenhagen S, Denmark and 7Centre for Pharmacogenomics, University of Copenhagen, 2200 Copenhagen N, 
Denmark
Email: Line Olsen - line.olsen@shh.regionh.dk; Thomas Hansen - thomas.hansen@shh.regionh.dk; 
Klaus D Jakobsen - klaus.damgaard.jakobsen@shh.regionh.dk; Srdjan Djurovic - srdjan.djurovic@medisin.uio.no; 
Ingrid Melle - ingrid.melle@medisin.uio.no; Ingrid Agartz - ingrid.agartz@medisin.uio.no; Haakan Hall - Hakan.Hall@ge.com; 
Henrik Ullum - henrik.ullum@rh.regionh.dk; Sally Timm - Sally.Timm@frh.regionh.dk; August G Wang - agwang@get2net.dk; 
Erik G Jönsson - Erik.Jonsson@ki.se; Ole A Andreassen - o.a.andreassen@medisin.uio.no; Thomas Werge* - thomas.werge@shh.regionh.dk
* Corresponding author    
Abstract
Background: Schizophrenia is a highly heritable complex psychiatric disorder with an underlying pathophysiology that
is still not well understood. Metaanalyses of schizophrenia linkage studies indicate numerous but rather large disease-
associated genomic regions, whereas accumulating gene- and protein expression studies have indicated an equally large
set of candidate genes that only partially overlap linkage genes. A thorough assessment, beyond the resolution of current
GWA studies, of the disease risk conferred by the numerous schizophrenia candidate genes is a daunting and presently
not feasible task. We undertook these challenges by using an established clinical paradigm, the estrogen hypothesis of
schizophrenia, as the criterion to select candidates among the numerous genes experimentally implicated in
schizophrenia. Bioinformatic tools were used to build and priorities the signaling networks implicated by the candidate
genes resulting from the estrogen selection. We identified ten candidate genes using this approach that are all active in
glucose metabolism and particularly in the glycolysis. Thus, we tested the hypothesis that variants of the glycolytic genes
are associated with schizophrenia or at least with gender-associated aspects of the illness.
Results: We genotyped 185 SNPs in three independent case-control samples of Scandinavian origin (a total of 765
patients and 1274 control subjects). Variants of the mitogen-activated protein kinase 14 gene (MAPK14) and the
phosphoenolpyruvate carboxykinase 1 (PCK1) and fructose-1,6-biphosphatase (FBP1) were nominal significantly
associated with schizophrenia, and several haplotypes within enolase 2 gene (ENO2) consist of the same SNP allele having
elevated risk of schizophrenia. Importantly, we find no evidence of stratification due to nationality or gender.
Conclusion: Several gene variants in the Glycolysis were associated with schizophrenia in three independent samples.
However, the findings are weak and not resistant to correction for multiple testing, which may indicate that they are
either spurious or may relate to a particular subtype or aspect of the illness.
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Schizophrenia is a severe psychiatric disorder with a
strong genetic component and a complex mode of inher-
itance[1]. The traditional, unbiased studies of linkage
analysis and positional cloning have identified a few cred-
ible risk genes of schizophrenia but have also fallen short
of providing definitive results as to the actual risk alleles
[2]. Although recent years have seen a growing number of
association studies of candidate genes proposed to under-
lie possible deviant biochemical parameters of specific
clinical phenotypes or deficient physiological processes in
schizophrenia patients, few findings have yet been repli-
cated [3].
A likely cause of the limited success of psychiatric genetics
is the complexity of these diseases that are widely assumed
to arise from an array of genetic and environmental risk
factors. As a probable consequence of this complexity, the
identification of genetic liability variants for schizophre-
nia has proven difficult and thus, the biological basis for
the illness is still not well understood. Indeed, a specific
clinical phenotype may well result from several risk genes
affecting the same biological process as genes do not act
alone but rather interact with one another or with envi-
ronmental factors to modulate cellular systems[4].
The recent advance in functional-genomics studies of post
mortem brains has led to new interesting hypotheses on
the etiology of schizophrenia [5]. Importantly, expression
studies on post-mortem human brain [6], of non-CNS tis-
sue or body fluids [7] have been able to implicate hun-
dreds of genes or proteins in pathology of the illness.
However, these findings are likely to include a considera-
ble number of false positives due to well-recognized cave-
ats of post-mortem studies such as variation in the post-
mortem interval, prior medication, drug abuse and age.
Similarly, expression studies outside the brain will neces-
sarily be flawed by factors that are unrelated to the schiz-
ophrenia pathology in the brain.
The challenge, therefore, is to develop a strategy that col-
lectively interpret and employ the massive, disease-related
data sets produced by unbiased (i.e. none-hypothesis
driven) linkage and expression studies. This may be
achieved through the use of a broadly accepted hypothesis
of schizophrenia to single out genes and proteins from the
unbiased experimental data sets that are more likely
linked to the etiology or pathology of the disease. One
compilation of widely accepted clinical and epidemiolog-
ical characteristics of schizophrenia is that age of onset,
symptomatology and outcome of antipsychotic treatment
differ between men and women (reviewed in [8]). The
estrogen hypothesis has been proposed to account for
these gender differences and suggests that estrogen pro-
vides protection from the development of schizophrenia
and mitigates the severity of negative symptoms[9,10].
Several clinical observations support the estrogen hypoth-
esis. These include fluctuation of psychotic symptoms in
schizophrenic women during their menstruation cycle
[11-14] and indications of a higher efficacy of antipsy-
chotic treatment in schizophrenia women than in
men[15]. Finally, there are also reports on reduced levels
of plasma estrogen in both male[16] and female[14,17-
19] schizophrenia patients. It is known that estrogen has
pleiotrophic effects on a variety of processes in the devel-
oping and adult brain [20-23], and therefore estrogen-
mediated signaling cascades rather than estrogen itself are
candidate pathways that may affect the risk of or modify
the manifestation of schizophrenia. This implies that
while estrogen varies enormously between and within
gender, the putative schizophrenia risk genes downstream
of estrogen need not differ between men and women.
Thus, we exploit the assumption that some risk genes of
schizophrenia are subject to estrogen regulation to postu-
late that the most likely candidates among the unbiased,
disease-related genes and proteins are those involved in
estrogen mediated signaling or transcription or estrogen
metabolism. Subsequently, we have grouped these estro-
gen-responsive and disease-related candidate genes
according to their involvement in well-known cellular
pathways. The best-defined candidate network that was
generated contained genes that are all involved in glucose
metabolism. Based on these combined lines of evidence
we have tested if genetic variants of ten genes involved in
glucose metabolism are associated with schizophrenia
using a case-control study design on three independent
samples of Scandinavian origin.
Results
We have screened ten candidate genes due to their rela-
tionship to the estrogen hypothesis and their deregulation
in – or linkage to schizophrenia. The genes were selected
using an approach, which integrates data from different
experimental sources as described in the material and
methods section. The expression profile or linkage to
schizophrenia for the ten genes is summarized in Table 2.
Single SNP association analysis
Allele frequencies between the case and control groups
were compared and adjusted for stratification due to
nationality and gender, respectively. Among the 156 ana-
lyzed SNPs, five SNPs within three genes obtained nomi-
nal P-values (< 0.05) when adjusting for nationality
(Table 3 & Additional file 1). Three of these five SNPs
reside within the MAPK14 gene. Although, the minor
allele frequencies of these SNPs are low their odds ratios
point in the same direction and suggest that variants of
MAPK14 could provide protection against schizophrenia.
The C alleles of both rs4129219 and rs1040566 in each ofPage 2 of 13
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with elevated risk for schizophrenia (Table 3). There was
no significant evidence for heterogeneity of the odds ratio
between countries for these five SNPs (Table 3). The
results were similar when we adjusted for gender as the
odds ratios and the corresponding p-values were only
marginally altered as compared to the results above (Table
3). Furthermore, we found no evidence for gender stratifi-
cation as reflected in the non-significant outcome of the
Breslow-Day test (Table 3).
Haplotype association analysis
Haplotype analyses were conducted for SNPs within LD
blocks of each gene individually. Only haplotypes within
one gene (ENO2) showed a nominal significant effect
(Table 4). We did not find evidence of stratification due to
gender or the presence of different nationalities in the
sample. Although, none of the SNPs within the ENO2
haplotypes were significantly associated in the single
locus allele tests one four-marker ENO2 haplotype (A-T-
A-T of rs2238116, rs1057077, rs710415, rs3213434,
respectively) showed significant association (Table 4). As
can be seen in Table 4 all of the two and three marker
combinations within this haplotype, which includes the T
allele of the rs3213434 locus, also had significant p-val-
ues.
The rs6908372 marker of MAPK14, which showed single
marker association, falls in a LD block that contains one
additional tagSNP (rs851017). The haplotype analysis of
these two loci showed a borderline effect (P = 0.07) with
an estimated haplotype frequency of the significant allele
(T-C) of 0.01 and 0.02 in cases and controls, respectively
and an odds ratio of 0.58 (CI (95%): 0.33–1.01, P = 0.04).
The remaining four of the five SNPs, which showed single
marker association for MAPK14, FBP1 and PCK1 are sin-
gle tagSNPs for separate LD blocks (i.e. we have no data
for other gene variants within these blocks).
Analysis of pair wise SNP interactions
PLINK was employed for the analysis of epistatic effects of
genetic variants among the nine SNPs, which showed
nominal association signals in either the allele or the hap-
lotype test. However, we found no significant differences
in any of the pair wise odds ratios between cases and con-
trols suggesting that there are no interactions among these
nine markers (data not shown).
Combined analysis across genes
Two statistical strategies were applied in order to attempt
to establish the study hypothesis by combining evidence
across genes. First, we asked whether the number of nom-
inally significant genes were higher than expected by
chance. The total number genes nominally associated
with schizophrenia (four out of the ten genes examined:
three genes by the single marker analyses and one gene by
the haplotype analyses) was compared to that expected by
change at the 0.05 significance level. This is a significant
excess of what would be expected by chance (p < 0.001)
and argues in favor of the overall hypothesis that glucose
metabolism is implicated in schizophrenia. Second, we
applied the truncated product p-value method that takes
all computed p-values into account [Zaykin et al., 2002].
This analysis did not, however, provide support for the
study hypothesis in total or gene-wise (p > 0.33).
Formal correction for multiple testing
A conservative correction for multiple testing of the single
locus analysis would imply considering all 156 SNPs that
have been assayed. However, the 156 analyses are not
Table 1: Sample characteristics
Schizophrenia Control
Sample Women (SD) Men (SD) Women (SD) Men (SD)
Denmark
N 160 224 330 478
Mean age 45.9 (12.3) 43.6 (11.6) 45.7 (12.0) 43.3 (11.2)
MAFA 28.4 (10.6) 26.4 (8.1)
Sweden
N 97 160 111 182
Mean age 57.1 (16.7) 52.3 (13.8) 50.7 (10.1) 50.1 (10.0)
MAFA 25.9 (8.0) 23.8 (5.9)
Norway
N 57 67 97 76
Mean age 38.3 (11.3) 35.3 (10.3) 38.1 (10.1) 40.1 (10.1)
MAFA 26.2 (8.7) 25.9 (9.1)
Mean age is calculated as the expected mean age in 2006; MAFA: mean age at first admission.Page 3 of 13
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156 different hypotheses but rather ten, one hypothesis
for each gene selected in the study. Secondly, the 156
SNPs are not independent, many of them being in high
LD. Thus, the least strict correction would be by the
number of genes, i.e. by a factor of ten. In either case none
of the single locus findings survive correction. A similar
rational could be applied to the haplotype analysis. None
of these resist correction for the number of SNPs or the
number of haploblocks analyzed. However, the haplotype
findings do seem to oppose the much less restrictive cor-
rection by the number of examined genes.
Discussion
In this study we present a novel method to select unbiased
candidate genes for association studies. We use experi-
mental data from schizophrenia studies on gene expres-
sion and linkage analysis – i.e. techniques that are
generally hypothesis-free approaches – and combine
them with the well-founded clinical and epidemiological
hypothesis of neuroprotective effect of estrogen. The
hypothesis serves as a clinical or biological filter that
reduces the noise in the experimental data sets by elimi-
nating genes that were found by chance in the studies on
gene expression or linkage analysis. As the final selection
criteria, we only consider genes that are classified as con-
stituting a functional signaling network. Using this step-
wise approach we found that the glycolysis is a plausible
candidate network of schizophrenia, being compatible
with both unbiased experimental data and with one of the
most well established hypothesis of the disease. Impor-
tantly, the brain relies almost exclusively on glucose for its
Table 2: Reported alterations in expression pattern, linked markers and the number of 185 SNPs tested for each of the 10 candidate 
genes
# Gene name Symbol Chr SNP1 Altered expressional2 Linked marker(s)3 pmid
mRNA
1. Enolase 2 (gamma, neuronal) ENO2 12p13 4 Prefrontal cortex (↑) 15474909
2. Glycogen synthase kinase 3 
beta
GSK3B 3q13.3 34 Hippocampus (↓) 12363385
3. Mitogen-activated protein 
kinase 14
MAPK14 6p21 40 Dorsolateral prefrontal 
cortex (↓)
12363385, 15098003
4. Phosphoglycerate mutase 1 
(brain)
PGAM1 10q25.3 11 Prefrontal cortex (↓) 11576761
PROTEIN
5. Enolase 1, (alpha) ENO1 1p36.2 5 Prefrontal cortex (↓) 15098003
1. Enolase 2 (gamma, neuronal) ENO2 12p13 - Prefrontal cortex (↓) 15098003
6. Glyceraldehyde-3-phosphate 
dehydrogenase
GAPDH 12p13 3 Prefrontal cortex (↓) 15098003
2. Glycogen synthase kinase 3 
beta
GSK3B 3q13.3 - Prefrontal cortex (↓), frontal 
cortex (↓)
15098003, 11290401
7. Hexokinase 1 HK1 10q22 32 Prefrontal cortex (↑, ↓) 10784483, 15098003
4. Phosphoglycerate mutase 1 
(brain)
PGAM1 10q25.3 - Prefrontal cortex (↓) 15098003
LINKAGE
4. Phosphoglycerate mutase 1 
(brain)
PGAM1 10q25.3 - D10S677 9754621
8. Phosphoenolpyruvate 
carboxykinase 2
PCK2 14q31.1 4 D14S70 12808429
9. Phosphoenolpyruvate 
carboxykinase 1
PCK1 20q13.31 8 D20S100 11803533
10. Fructose-1,6-bisphosphatase 
1
FBP1 9q21.33 15 D9S1812 12808429
3. Mitogen-activated protein 
kinase 14
MAPK14 6p21 - D6S1610, D6S271, 12929083,11126394,
D6S291, HLADQA, 12140777,7581457
HLADQB, HLA-DQB1,
HLADRB1, D6S273,
HLAA, D6S464
1 The number of heterogeneous SNPs investigated for each gene in the current study
2 Tissue and the direction of expression alterations in schizophrenia as compared to control subjects. ↓: Reduced expression, ↑: Elevated 
expression
3 Markers with suggestive evidence for linkage to schizophrenia in the vicinity of the given genePage 4 of 13
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lytic processes are mandatory for proper brain develop-
ment and function. Nonetheless, the functional
relatedness between the glycolytic genes in the unbiased
data sets has not been realized earlier. Four aspects emerge
from the study that merit particular commenting.
Firstly, it is important to emphasize that the selection pro-
cedure chosen in this study – albeit based on data from
unbiased studies on gene expression and linkage analysis
– is itself biased by the choice of clinical hypothesis that is
used to filter the experimental input data and by the cur-
rent knowledge on biological networks that is used to rec-
ognize and prioritize the identified gene clusters.
However, we consider this type of bias to be a positive fea-
ture of our selection method that fundamentally allows
any well-formulated hypothesis to be tested against the
collection of unbiased experimental data available at any
given time.
Secondly, the study focused on genes that affect glucose
metabolism and their involvement in schizophrenia and
we have completed an association screen of ten candidate
genes for schizophrenia in a large Scandinavian sample.
We aimed to provide high coverage of each gene by select-
ing (i) a set of tagSNPs that characterized common varia-
tion across each gene or (ii) as many of the known SNPs
with a maf > 0.01 in Caucasians. We have highlighted the
most promising single- and multi marker associations on
the basis of nominal P-values.
In the single marker analyses we identified three genes
containing one or more SNPs with a nominal significant
effect and multi marker association analysis identified
one additional gene (ENO2). All five SNPs, which showed
single locus association to schizophrenia, are located in
introns and have been selected as tagSNPs for LD blocks.
They may therefore not represent causative SNPs but
rather be in LD with true disease susceptibility variants.
Although the allele frequencies for the risk variants of
rs4129219 (FBP1) and rs1040566 (PCK1) are somewhat
larger than those observed for the 3 MAPK14 SNPs the
odds ratios (OR: 1.20 and 1.27 for FBP1 and PCK1,
respectively) are relatively low even for complex condi-
tions.
Multi marker analysis revealed that the significant ENO2
haplotypes all includes the T allele of the rs3213434 locus
although the single locus allelic test of this polymorphism
is not significant on it's own. This suggests that the signif-
icant ENO2 haplotype(s) tag a true causative associated
variant(s), which seem to have originated on a haplotype
background of carriers of the rs3213434 T allele. The sta-
tistics for combined effect of the two MAPK14 markers is
uncertain, as the confidence interval for the significant T-
C haplotype is fairly broad. Also, P-values for all five sin-
gle markers as well as for the ENO2 haplotypes are non-
significant if adjusted for multiple testing.
One main reason for the difficulty in identifying signifi-
cant risk alleles is presumably small effect sizes. In fact,
this study was able with a power = 0.8 to detect odds ratios
larger than 2.8 for the SNP with the minimal MAF (= 1%)
and ORs larger than 1.28 for the SNP with the maximal
MAF (= 49%) analyzed in this study (Supplementary
Table 1). The possibility also exists that the disease suscep-
tibility genes are not shared among all individuals thus
making them harder to identify. Furthermore, several risk
genes may interact and thereby jointly increase the overall
risk for developing schizophrenia. Ideally, interaction
analyses between genes should therefore be performed to
address this complexity. However, this provides addi-
Table 3: Minor allele frequency and associated p-values for markers showing nominal significant allelic effect
Allelic association adjusted for
Minor allele frequency Nationality Gender
Gene Marker Variants1 Cases Controls OR CI (95%) Pnat (PBD)2 Psex (PBD)3
MAPK14 rs9470207 C/T 0.01 0.02 0.52 (0.30–0.92) 0.02 (0.25) 0.02 (0.97)
MAPK14 rs6908372 T/A 0.01 0.02 0.54 (0.31–0.96) 0.03 (0.25) 0.03 (0.93)
MAPK14 rs9462156 A/G 0.01 0.02 0.56 (0.32–1.00) 0.04 (0.36) 0.04 (0.91)
PCK1 rs1040566 C/A 0.11 0.09 1.27 (1.02–1.59) 0.04 (0.82) 0.05 (0.23)
FBP1 rs4129219 C/T 0.19 0.17 1.20 (1.01–1.43) 0.04 (0.92) 0.09 (0.45)
OR: odds ratio, CI(95%): 95% confidence interval for the OR
1 The minor allele is give prior to the major allele
2P-values are for the Cochrane-Mantel-Haenszel tests adjusted for potential presence of stratification between countries. P-values for the Breslow-
Day test statistics for odds ratio heterogeneity between countries are given in ()
3P-values are for the Cochrane-Mantel-Haenszel tests adjusted for potential presence of stratification between men and women in all 3 countries. 
P-values for the Breslow-Day test statistics for OR heterogeneity between gender are given in ()Page 5 of 13
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gene variants in several (or many) genes. As our set up
invites for combined analyses of the different genes we
performed post hoc interaction analyses among the nine
SNPs, which showed nominal association signals in either
the allele or the haplotype test but found no evidence for
such interactions. Although the presences of interactions
between other markers are overlooked we restricted the
analysis to the nine markers to limit the number of tests
to be performed.
Thirdly, gender differences are well-established in schizo-
phrenia and the immense literature on the subject empha-
ses the importance of taking these differences into account
when searching for biological susceptibility factor for this
disorder[24]. The estrogen hypothesis – formulated to
account for these differences – suggests that the observed
symptom variability between men and women (e.g. in age
of onset, affective and flat features) is related to estrogen.
However, estrogen may not be directly involved in schiz-
ophrenia pathogenesis. Rather, we have based the current
study on the assumption that schizophrenia susceptibility
genes are regulated by estrogen. The rationale behind this
assumption rests on the growing evidence that estrogen
affects a variety of processes in the developing and adult
brain, including neuronal differentiation, survival and
excitability (reviewed in[25,26]) as well as on glial prolif-
eration and synaptic plasticity (Reviewed by[22,27]).
Also, estrogen is known from animal studies to regulate
several neurotransmitter systems[22,28] (dopamine, sero-
tonin, noradrenalin and glutamate) implicated in schizo-
phrenia.
We find no significant gender differences in the SNPs
related to glucose metabolism, selected because of their
compatibility with the estrogen hypothesis. This may at a
first glance seem unexpected. However, the strategy in this
study is not based on the assumption that estrogen itself
Table 4: ENO2 haplotypes showing nominal significant association to schizophrenia
Model effect1 Individual effect
Overall Country Case Control
Markers P P n (freq) n (freq) OR (CI: 95%) P2
rs2238116, rs3213434 0.01 0.59
AC* 1030 (0.72) 1730 (0.71) 1.00 (1.00-1.00) 0.51
AT 20 (0.01) 69 (0.03) 0.48 (0.29–0.80) 0.0007
GT 388 (0.27) 655 (0.27) 1.00 (0.86–1.17) 0.74
rs1057077, rs3213434 0.0026 0.32
TC* 1087 (0.72) 1782 (0.70) 1.00 (1.00-1.00) 0.33
TT 18 (0.01) 69 (0.03) 0.42 (0.35–0.51) 0.0006
AT 403 (0.27) 679 (0.27) 0.99 (0.58–1.69) 0.92
rs710415, rs3213434 0.01 0.37
AC* 1091 (0.72) 1772 (0.71) 1.00 (1.00-1.00) 0.31
AT 18 (0.01) 63 (0.03) 0.46 (0.27–0.79) 0.0009
GT 399 (0.26) 675 (0.27) 0.97 (0.84–1.13) 0.92
rs2238116, rs1057077, rs3213434 0.0045 0.59
ATC* 1021 (0.72) 1725 (0.71) 1.00 (1.00-1.00) 0.57
ATT 17 (0.01) 66 (0.03) 0.43 (0.36–0.52) 0.001
GAT 388 (0.27) 653 (0.27) 1.01 (0.83–1.23) 0.71
rs2238116, rs710415, rs3213434 0.01 0.61
AAC* 1025 (0.72) 1712 (0.71) 1.00 (1.00-1.00) 0.63
AAT 17 (0.01) 61 (0.03) 0.47 (0.27–0.81) 0.001
GGT 386 (0.27) 643 (0.27) 1.01 (0.87–1.18) 0.67
rs1057077, rs710415, rs3213434 0.01 0.32
TAC* 1085 (0.72) 1765 (0.71) 1.00 (1.00-1.00) 0.50
TAT 18 (0.01) 63 (0.03) 0.47 (0.47–0.47) 0.004
AGT 399 (0.27) 668 (0.27) 0.99 (0.99-0.99) 0.95
rs2238116, rs1057077, rs710415, 0.01 0.60
rs3213434
ATAC* 1019 (0.72) 1710 (0.71) 1.00 (1.00-1.00) 0.68
ATAT 17 (0.01) 61 (0.03) 0.47 (0.39–0.57) 0.004
GAGT 386 (0.27) 643 (0.27) 1.02 (0.84–1.24) 0.70
*Reference haplotype with odds ratio (OR) set to 1.00
1 P-values for the overall effect of a model containing the given loci and the presence of stratification due to differences between the 3 countries.
2 P-value for the individual haplotype adjusted for nationalityPage 6 of 13
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and epidemiological observations that indicate that estro-
gen affects liability or the clinical manifestation of the dis-
ease. If this assumption is true, then the estrogen-
signaling network is functionally coupled to the cellular
or physiological processes that predispose to schizophre-
nia that we attempt to identify. Importantly, the risk asso-
ciated with disease-disposing alleles downstream of
estrogen need not differ between men and women, while
the clinical estrogen-effects do fluctuate as a consequence
of the inherent gender-related variations in the metabo-
lism of estrogen[14,29-31].
Finally, to our knowledge there have been no previous
studies reporting association between the glycolytic genes
investigated in the present study and schizophrenia. As we
cannot draw firm conclusions with the current data fur-
ther investigations with testing of more loci are required
to clarify whether ENO2, FBP1, MAPK14 and PCK1 vari-
ants provide genetic support for the view that alterations
in glucose metabolism are intrinsic to schizophrenia etiol-
ogy.
We only examined genes in the glycolysis that are also
subject to estrogen regulation. Thus, other genes involved
in glucose regulation that could be implicated in schizo-
phrenia, were not included in this study due to our sam-
pling scheme for candidate genes. Indeed, Stone et al[32]
have found linkage between another glycolytic gene (6-
phosphofructose-2-kinase) and schizophrenia in a mixed
sample of African and European Americans. This finding
has not been replicated in other samples. Both the Stone
study and ours encourage to pursue the hypothesis that
glucose metabolism is involved in schizophrenia.
Co-morbidity between schizophrenia and diabetes has
been known for decades[33] and reports on abnormal
glucose regulation go back more than half a century
(e.g.[34,35]). However, the involvement of abnormal glu-
cose regulation in the pathology and etiology of schizo-
phrenia has not received much attention until obesity,
hyperglycemic and hyperlipidemia effects was found to be
associated with some of the newer, atypical antipsychotic
drugs[36,37]. These observations have stimulated specu-
lations that some antipsychotic drugs accelerate pre-exist-
ing perturbation of glucose metabolism in schizophrenic
patients and thereby reveal an otherwise hidden biologi-
cal basis for the disorders[38]. Indeed, a recent study by
Bahn and colleagues found that elevated glucose levels in
cerebrospinal fluid in drug-naïve patients were normal-
ized upon antipsychotic medication[39]. This and other
studies by the same group seem to suggest that compro-
mised energy metabolism in particular in response to oxi-
dative stress is intrinsic to schizophrenia [40-42].
Interestingly, oxidative stress itself has recently been
linked to schizophrenia[43] possibly hinting at a disease-
susceptible regulatory network in the brain.
Conclusion
In conclusion, we failed to provide convincing evidence in
support of the hypothesis that genetic variations in the
investigated glycolytic genes are involved in the etiology
of schizophrenia. Indeed, the data do encourage contin-
ued investigations on the role of glucose metabolism in
this disorder. Especially, more data on the genes, which
have shown nominal effects in this and other studies as
well as other glycolytic genes, are needed to evaluate if
dysregulation of glucose metabolism is inherent to schiz-
ophrenia.
Methods
2.1 Strategy for candidate gene selection
The candidate genes that are analyzed in this study are
involved in a well-defined cellular network and have been
selected using a three-step strategy, which integrates func-
tional genomics data, findings from linkage analyses and
a well-founded clinical and epidemiological hypothesis.
Step 1. Genes were selected according to the following two
criteria: (I) they have been shown in previous studies to be
differentially expressed (at the mRNA and/or protein
level) in brain tissues of schizophrenia patients as com-
pared to non-psychiatric control subjects, or (II) they are
localized within +/- 1 mb of a genetic marker that have
shown suggestive evidence for linkage to schizophrenia
(LOD-score ≥ 2). Step 2. Genes or proteins involved either
in the estrogen metabolism or are regulated by estrogen
were selected among the genes identified in step 1. Step 3.
The cellular signaling networks that are represented by
genes or proteins selected in step 2 were identified and
prioritized. The top-ranking network was selected for gen-
otyping analysis.
Literature search
A systematic search in PUBMED (release April 16. 2006)
for papers on schizophrenia resulted in 241 references
covering three experimental areas: gene-(113) and protein
(98) expression and linkage (35) studies. We only consid-
ered data represented with statistical support in the origi-
nal paper that were altered at the mRNA and/or protein
level in schizophrenia brain samples – and/or potentially
associated with schizophrenia due to their genomic posi-
tion close to markers with suggestive linkage with schizo-
phrenia.
Gene and protein expression data on schizophrenia (step 1a)
The gene expression data include reports from micro-
array, RT qPCR, in situ hybridization, and Northern Blot-
ting studies. Data for protein expression was collected
from studies based on immunohistochemistry, WesternPage 7 of 13
(page number not for citation purposes)
BMC Medical Genetics 2008, 9:39 http://www.biomedcentral.com/1471-2350/9/39Blotting, ELISA and 2D gel electrophoresis. In total, we
identified 339 genes and 115 proteins that have been
reported with differential brain expression in patients
with schizophrenia as compared to non-psychiatric con-
trol subjects, regardless of tissue specific expression.
Linkage data on schizophrenia (step 1b)
Data on genetic markers showing linkage to schizophre-
nia were collected from linkage studies based on extended
family- or affected sib pair methods. Genes situated
within nearby genomic regions of each genetic marker
were extracted from the Ensemble genome database
(release 38). Overall, 134 markers were reported having
suggestive evidence for linkage (LOD score 2) to schizo-
phrenia in at least one study. A total of 1339 protein cod-
ing genes are located within +/- 1 mb of these markers.
Estrogen responsive genes (step 2)
Information on genes that are regulated by estrogen were
obtained from the Dragon Estrogen Responsive Genes
Database (ERGDB)[44] and genes involved in estrogen
metabolism, signaling or transcription were identified
from public literature databases using two literature min-
ing tools: Information Hyperlinked over Proteins
(iHOP)[45] and Pathway assist[46]. A total of 2239 estro-
gen responsive genes were identified. Among these, 302
genes were identified among the 1751 disease-related
genes identified in step 1a & b (above); 148 of the 302
genes were implicated by gene (111) or protein (53)
expression studies, whereas 154 genes came from linkage
studies. Only eight of the 302 estrogen-selected genes
were implicated by both expression and by linkage stud-
ies. No single gene was implicated in all three criteria gene
expression, protein expression and linkage data.
Selection of candidate genes from biological networks (step 3)
The final selection of candidate genes was performed by
first identifying and prioritizing the biological networks
represented by the 302 genes resulting from step 2. To
identify these biological networks we have used the Data-
base for Annotation, Visualization, and Integrated Discov-
ery (DAVID v. beta2)[47]. DAVID is a tool for
construction of functional networks among genes based
on Gene Ontology (GO), on protein structure databases
and on the Kyoto Encyclopaedia of Genes and Genomes
(KEGG)[48]. Using the options for "Gene Functional
Classification" and "medium stringency" 13 groups were
constructed and prioritized according to their Group
Enrichment Score that ranks the biological significance of
gene groups based on overall EASE scores of all enriched
annotation terms[47].
Each group of genes was also evaluated manually. The
seven lowest ranking groups contained proteins perform-
ing similar, general functions (e.g. transporters, receptors,
kinases, transcription factors), but which otherwise had
no direct cellular relations. Another five clusters were
loosely defined through their association to general
molecular mechanisms that did not constitute a formal
signaling pathway or network (e.g. macromolecular
metabolism or cellular defense) and were also disregarded
in the present study. In contrast, the remaining cluster
contained five genes (i.e. Enolase 1 [ENO1], Enolase 2
[ENO2], Glyceraldehyde-3-phosphate dehydrogenase
[GAPDH], Hexokinase 1 [HK1] and Phosphoglycerate
mutase 1 [PGAM1]) that all participate in a single and
well-defined cellular process – namely the glycolysis – and
were therefore selected as a "genuine" biological network
for further analysis.
Another two genes were also chosen for analysis although
they were classified into the second-ranked group of
"macromolecular metabolism" since they are important
for regulation of glucose metabolism (i.e. Glycogen syn-
thase kinase 3 beta (GSK3B) and Mitogen-activated pro-
tein kinase 14 (MAPK14)). Furthermore, inspection of an
extended data set from the linkage analysis studies that
contained genes within +/- 10 mb of a genetic marker
showing association to schizophrenia (with a LOD score
≥ 2) revealed three additional genes involved in sugar
homeostasis (Phosphoenolpyruvate carboxykinase 1
(PCK1), Phosphoenolpyruvate carboxykinase 2 (PCK2)
and Fructose-1,6-bisphosphatase 1 (FBP1)). These three
genes were also included into the final data set of 10 can-
didate genes. Figure 1 gives an overview of the involve-
ment in glucose metabolism for these genes. Finally, the
relationship between the selected disease candidate genes
and estrogen were confirmed by manual inspection of the
relevant literature.
Data storage
The individual gene or protein information was systemat-
ically stored in a MySQL relational database. To facilitate
integration of data from the numerous studies the official
HGNC nomenclature (Aug 2005 update) for gene names
and symbols were obtained for each gene or the gene cod-
ing for a given protein.
2.2 Sample
This study included a Scandinavian case-control sample
composed of three independent population-based sam-
ples of Danish, Swedish and Norwegian origin from
which recent non-European ancestry had been excluded.
Overall the sample includes 765 cases and 1274 control
subjects. The characteristics for the three samples are sum-
marized in Table 1.
The Danish sample
The Danish sample included 384 patients who have been
recruited to Danish Psychiatric Biobank from the psychi-Page 8 of 13
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region. All patients had been clinically diagnosed with
schizophrenia according to ICD-10; F20 (n = 345), F21 (n
= 6), F22 (n = 5) and F25 (n = 28) without ever having
received a diagnosis of mania or bipolar illness (F30-31).
An experienced research- and consultant psychiatrist veri-
fied high reliability of the clinical diagnoses [49,50] using
OPCRIT semi-structured interviews. The vast majority of
the patients (96%) who fulfilled the ICD-10 criteria of
schizophrenia also complied with the corresponding
DSM-IV standards. At the time of the last assessment the
patients had a mean age of 44.5 (+/- 12.0) years, a mean
age at onset of illness of 27.1 (+/- 11.2) years, a mean
duration of illness of 17.3 (+/- 10.4) and a mean duration
of hospitalization of 12.8 (+/- 8.6) years. None of these
variables differed significantly between men and women.
The majority (87%) of the patients were ethnical Danish,
i.e. the patients and both parents were born in Denmark,
while in a minor fraction of the cases (13%) one Cauca-
sian parent was born outside Denmark in another North-
Western European country, primarily in Sweden or Nor-
way, secondarily in Germany, the Netherlands, England
or France.
The healthy controls subjects were anonymously selected
among 72,000 unpaid voluntary blood-donors from the
Blood Donor Corps in the Copenhagen area. The Donor
corps includes 4.9% of the adult population aged 18–65
years. Apparent behavioral abnormality was an exclusion
criterion and all individuals stated that they felt com-
pletely healthy with a possibility to discuss any health
related issues with a physician. Each patient was matched
to on gender, year of birth and month of birth to two
Overview of the ten identified candidate genes and their involvement in glucose metabolismFigure 1
Overview of the ten identified candidate genes and their involvement in glucose metabolism. The glucolysis is 
shown as a white vertical arrow in which the relevant substrates & products are listed. The ten candidate genes are shown in 
rounded boxes.
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background.
The Danish Scientific Committees (J.nr. 01-024/01) and
the Danish Data Protection Agency (J.nr. 2001-54-0798)
approved the study and all the patients have give written
informed consent prior to inclusion into the project.
The Swedish sample
The Swedish sample included 257 patients who have been
recruited from psychiatric clinics in northwestern Stock-
holm County. All patients had been clinically diagnosed
with schizophrenia (n = 224), schizophreniform disorder
(n = 8) or schizoaffective disorder (n = 25) according to
DSM-III-R/DSM-IV diagnostic criteria based on interviews
and record reviews as previously described. [51-53]
At the time of the last assessment the patients had a mean
age of 43.6 (+/- 14.2) years, a mean age at onset of illness
of 24.6 (+/- 6.8) years, and a mean duration of illness of
19.0 (+/- 13.8) years. Psychotic women were older when
entering the study (46.9 +/-15.5 years), and tended to
have a higher age at onset (25.8 +/- 8.0 years) and a longer
duration of illness (21.0 +/- 14.7 years) than men with
psychosis (41.6 +/- 13.1, 23.9 +/- 5.9 and 17.7 +/- 13.2
years; Wilcoxon/Kruskal Wallis tests p = 0.007, p = 0.07,
and p = 0.09, respectively). All patients were Caucasian.
Based on the birth country of the grandparents or greater
grandparents, 78%, 12% and 9% of the patients were esti-
mated to be of Swedish, Finnish or other European origin,
respectively. The healthy controls subjects were recruited
among subjects previous participating in biological psy-
chiatric research at the Karolinska Institute or drawn from
a representative register of the population in Stockholm
County and interviewed as previously described [54]. All
controls were Caucasian and 86%, 6%, and 8% were esti-
mated to be of Swedish, Finnish or other European origin,
respectively. The mean age of the participants when enter-
ing the study was 40.5 (+/- 9.8) years. None of the con-
trols suffered from schizophrenia.
The Ethical Committee of the Karolinska Hospital, the
Stockholm Regional Ethical Committee and the Swedish
Data Inspection Board approved the study. All subjects
participated after giving informed consent.
The Norwegian sample
The Norwegian sample included 124 patients who had
been recruited to the TOP study from all the psychiatric
hospitals in the Oslo area. The patients had been clinically
diagnosed according to Structural Clinical Interview for
DSM-IV (SCID) with schizophrenia (n = 99), schizoaffec-
tive (n = 19), and schizophreniform disorder (n = 6). Two
clinical professors continuously trained and supervised a
group of research fellows in order to secure the quality of
the clinical assessments. Reliability of the clinical diagno-
sis has recently been tested, and the percentage of agree-
ment was 82%, and Kappa 0.77 (95% CI: 0,60–0,94).
At the time of the last assessment the patients had a mean
age of 36.6 (+/- 10.9) years, a mean age at onset of illness
of 26.0 (+/- 9.0) years (onset defined as age of first contact
with psychiatric health service), and a mean duration of
illness of 10.6 (+/- 10.5) years. None of these variables dif-
fered significantly between men and women. The major-
ity (90%) of the patients were ethnical Norwegian, i.e. the
patient and both parents were born in Norway, while in a
minor fraction of the cases (10%) one parent was born
outside Norway in another North-western European
country.
The healthy controls subjects were randomly selected
from statistical records of persons from the same catch-
ments area as the patient groups. Only subjects born in
Norway were contacted by letter and invited to partici-
pate. All controls were of Caucasian origin; around 85 %
had two Norwegian parents, the rest one parent from
other European origin. Moreover, all participants had to
have Norwegian as their first language or have received
their compulsory schooling in Norway. The mean age of
the control subjects in 2006 was 39.0 (+/- 10.2) years. The
control subjects were screened by interview and with the
Primary Care Evaluation of Mental Disorders (PRIME-
MD). None of the control subjects had a history of mod-
erate/severe head injury, neurological disorder, mental
retardation or an age outside the age range of 18–60 years.
Healthy subjects were excluded if they or any of their close
relatives had a lifetime history of a severe psychiatric dis-
order (schizophrenia, bipolar disorder and major depres-
sion), a history of medical problems thought to interfere
with brain function (hypothyroidism, uncontrolled
hypertension and diabetes), or substance abuse.
The Norwegian Scientific-Ethical Committees (approval
no 493-03-01179) and the Norwegian Data Protection
Agency (approval no 2003/2052) approved the study and
all patients have given written informed consent prior to
inclusion into the project.
2.3 SNP selection
For each gene (including 500–2000 bp upstream of
exon1) TagSNPs were selected (R2>0.8) from genotype
data (allele frequency >.01) on the HapMap European
(CEU) sample (Build 35) using Tagger[55] implemented
in Haploview 3.2 [56] with the options for aggressive 2-
and 3-ways tagging. The selected TagSNPs provided sub-
stantial coverage of all reported SNPs in six of the ten
selected genes: GSK3B: 74 tagged of 106 total SNPs; HK1:
71 tagged of 154 total SNPs; MAPK14: 65 tagged of 72
total SNPs; PCK2: 5 tagged of 5 total SNPs; PCK1: 9 taggedPage 10 of 13
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limited HapMap data were available for remaining four
genes (ENO1, ENO2, GAPDH and PGAM1). Instead, all
SNPs reported in dbSNP (NCBI) with a minor allele fre-
quency (MAF) > 0.01 in European populations were cho-
sen for these genes.
2.4 Genotyping
Genomic DNA was extracted from whole blood samples.
Genotyping was performed using the GoldenGate assay
(Illumina Inc)[57] on custom designed Illumina high-
throughput Bead Arrays at the genotyping facility at Upp-
sala University, Sweden. An estimated genotype success
rate for each SNP, which takes into account both SNP val-
idation status and assay design for the array, put restric-
tions on the SNP panel that can be tested. Therefore, SNPs
less than 60 bp apart can not both be genotyped; when
this occurred we selected the SNP with the highest esti-
mated success rate, followed by highest MAF. For tagSNPs
selected from HapMap that did not fulfill the assay crite-
ria, additional SNPs within the same LD block were
selected instead. In total, we genotyped 185 SNPs across
the 10 candidate genes. A call-rate cut-off value equal to
0.90 was used to ensure genotype data with accuracy
above 0.98.
2.5 Statistics
Hardy-Weinberg equilibrium
We tested Hardy-Weinberg (HW) equilibrium using the
chi-square exact test implemented in the "GENETICS"
package for R on all heterozygous SNP markers in cases
and control subjects separately. SNPs in HW disequilib-
rium in the control were removed from the subsequent
analyses, while those in the patient group were not as dis-
equilibrium may arise due to selection of diseased indi-
viduals. It may be argued that correction multiple testing
should be performed prior to excluding SNPs in HWD.
However, we chose a conservative approach and insisted
that only SNPs in (nominal) HWE be analyzed. Overall,
185 markers were genotyped across the ten candidate
genes. Based on data from the total sample of 2039 per-
sons we found 21 to be monomorphic. Of the remaining
SNPs, eight and 13 showed nominal derivation from
Hardy-Weinberg proportions in the control and patients
group, respectively (P < 0.05). None of these SNPs were
deviating in both groups. Markers were exclude if either
monomorphic in the total sample or in HW disequilib-
rium in the control sample-.
Population stratification
We tested for stratification by computing Fst between the
three control-populations (Danish, Swedish and Norwe-
gian) across all polymorphic loci in the six examined
genes using Arlequin version 3.1[58]. We find no evidence
of population stratification between the healthy controls
across the six genes assessed together (Fst = 0.00057) or for
each of the genes individually (Fst [min] = -0.00077 and Fst
[max] = 0.0036).
Association tests
Test for allelic and haplotype association were done as a
joint analysis of all three samples. In these combined
analyses nationality or gender was included as a covariate
to adjust for the potential confounding. We chose to cor-
rect for these two variables in all initial analyses (despite
that Fst analysis indicated lack of population stratification)
as nationality is a proxy not only of the genetic back-
ground but also of the differences in the psychiatric health
care systems that may impact on which patients are
included into the study. Gender was also included as an
obligate confounder, as the study specifically focuses on a
gender related hypothesis, estrogen. We used a nominal
approach with a significance threshold of p < 0.05.
Single marker tests of association
For single marker analysis, nominal p-values were
obtained using the Cochran-Mantel-Haenszel test for 2 ×
2 × k tables in PLINK [59] (v. 0.99 p) in combination with
the Breslow-Day test for heterogeneity in the odds ratios
for the disease-SNP association between nationalities and
gender, respectively.
Multi marker tests of association
Haplotype tests of association were performed within LD
blocks of each gene using UNPHASED [60,61] (v. 3.0.5).
The block structure constructed from HAPMAP data dur-
ing tagSNP selection was used for FBP1, GSK3B, HK1,
MAPK14, PCK1 and PCK2. For ENO1, ENO2, GAPDH
and PGAM1 LD blocks were first defined from the geno-
type data using the default definition in HAPLOVIEW
[62]. In either case the LD blocks are constructed based on
the method of Gabriel et al. [63] in which a LD block is
formed if 95% of each pairwise SNP comparisons are in
'strong LD' (as defined by D prime). Estimated haplotype
frequencies <0.01 were set to zero and the options for
individual haplotype effect and confounder effects were
applied. All marker combinations and all windows sizes
were tested within each LD block.
Interaction analyses
The Z-score test for difference in pair wise SNP odds ratios
between cases and controls implemented in PLINK [59]
(v. 0.99 p) were conducted post hoc to test for pair wise
interactions of markers, which showed nominal associa-
tion signals in either allele or haplotype test.
Power analyses
Further, the Chi-Square "Goodness of Fit" Test was used to
estimate the chi-square difference between the expected
and the observed numbers of significant genes. The powerPage 11 of 13
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as derived from Rver.2.5.1: http://staff.pubhealth.ku.dk/
~ande/.
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